In humans, silymarin has been described to ameliorate glycemic control, with a reduction in both fasting insulin and exogenous insulin requirements in insulin‐treated patients with type 2 diabetes and hepatic cirrhosis (Voroneanu, Nistor, Dumea, Apetrii, & Covic, 2016). This evidence concerns the gene INS and type 2 diabetes mellitus.